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Clostridium difficile-associated diarrhoea (CDAD) is becoming 
increasingly common. It is a potentially life-threatening condition 
with mortality as high as 33% and a 28% possibility of relapse. [1] 
Risk factors for acquiring CDAD include increasing age (>65 years), 
multiple antibiotic treatments, lengthy stays in hospital and 
concurrent proton-pump inhibitor (PPI) therapy.[2] Most infections 
are healthcare associated, occurring in hospitals and long-term 
care facilities, but outpatient acquisition has also been described.[3] 
The disease is spread via the faecal-oral route by ingestion of acid-
resistant spores. Meticulous hand hygiene on the part of of healthcare 
workers, by washing with soap and water or disinfectants to help 
remove spores, is extremely important, and isolation of patients with 
acute diarrhoea can limit the spread of the disease in healthcare 
facilities.
The burden of this condition has been demonstrated clearly at Wits 
Donald Gordon Medical Centre (WDGMC), Johannesburg, South 
Africa (SA), through established active surveillance of hospital-
acquired infections as part of the infection prevention and control 
programme (Fig. 1).[4]
Much effort has been focused on patient therapies to prevent 
symptomatic disease. Probiotics have been used in the treatment of 
CDAD, but their role remains uncertain. A meta-analysis conducted 
in 2010 suggested that there may be a benefit to using probiotics in 
addition to standard therapy for the management of patients with 
severe or relapsing C. difficile infection (CDI) or to prevent infection. 
However, the studies included in the review were small and there are 
currently insufficient data to support the use of probiotics in patients 
with CDAD.[5] Recommended treatment for the disease is via the oral 
route using metronidazole or vancomycin, to which 90% of patients 
respond and experience no further symptoms.[6]
The major problem with CDAD is symptomatic recurrence after 
antimicrobial therapy is complete. The frequency of recurrence has 
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Background. Clostridium difficile-associated diarrhoea (CDAD) is a potentially life-threatening condition that is becoming increasingly 
common. A persistent burden of this infectious illness has been demonstrated over the past 4 years at Wits Donald Gordon Medical 
Centre (WDGMC), Johannesburg, South Africa, through implementation of active surveillance of hospital-acquired infections as part 
of the infection prevention and control programme. Oral treatment with metronidazole or vancomycin is recommended, but there is a 
major problem with symptomatic recurrence after treatment. Replacement of normal flora by the administration of donor stool through 
colonoscopy or nasogastric/duodenal routes is becoming increasingly popular.
Objectives. To identify risk factors for the development of CDAD in patients referred for faecal microbiota transplant (FMT) and evaluate 
the safety of administration of donor stool as an outpatient procedure, including via the nasogastric route.
Methods. A retrospective record review of patients with recurrent CDAD referred for FMT at WDGMC between 1 January 2012 and 31 
December 2016 was conducted.
Results. Twenty-seven patients were identified, all of whom fulfilled the criteria for recurrent CDAD. One-third were aged >65 years, and 
the majority were female. The most common risk factors were prior exposure to antibiotics or proton-pump inhibitors and underlying 
inflammatory bowel disease. Three procedures were carried out as inpatients and 24 in the outpatient gastroenterology unit. At 4-week 
follow-up, all patients reported clinical resolution of their diarrhoea after a single treatment and there were no recurrences. The FMT 
procedure was associated with no morbidity (with particular reference to the risk of aspiration when administered via the nasogastric 
route) or mortality.
Conclusions. This case series confirms that FMT is a safe and effective therapy for recurrent CDAD. In most cases it can be administered 
via the nasogastric route in the outpatient department. We propose that the recently published South African Gastroenterology Society 
guidelines be reviewed with regard to recommendations for the route of administration of FMT and hospital admission. Meticulous 
prescription practice by clinicians practising in hospitals and outpatient settings, with particular attention to antimicrobials and chronic 
medication, is urgently required to prevent this debilitating and potentially life-threatening condition.
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been reported to be as high as 50%, and if a patient has experienced 
one recurrence, the risk of subsequent recurrence is even higher. [7] 
Disruption of the normal gut microbiota is the main cause of 
susceptibility to and recurrence of infection. Replacement of normal 
flora is becoming an increasingly popular therapeutic intervention, 
and treatment by the administration of donor stool through 
colonoscopy or the nasogastric/duodenal route is well described. [7-9] 
Faecal microbiota transplant (FMT) is considered a safe and effective 
treatment for recurrent CDAD and has a reported success rate of 
80 - 90% from one infusion of donor stool.[7] While there are many 
published case series and reports confirming the efficacy of the 
treatment, to date there have only been two randomised controlled 
trials comparing FMT with current treatment, which includes 
extended vancomycin therapy. In both studies, early termination was 
recommended because the superiority of FMT made continuation 
unethical.[10,11] It is also noteworthy that patients who receive FMT 
experience minimal or no short-term complications, although the 
long-term consequences are unknown.[12]
There are no absolute contraindications to faecal transplantation. 
The choice to undergo faecal transplant has been positively 
influenced by its cost-effectiveness compared with continuing 
antibiotic treatment, as well as its success rate. Patients typically 
respond well to the idea of faecal transplantation, once the benefits 
of the procedure are explained to them, but the idea of the procedure 
is an obstacle to some.[13] The most acceptable and safe methods of 
administering FMT are nasogastric via insertion of a nasogastric 
tube (NGT), and into the large bowel via colonoscopy. Nasogastric 
administration is cost-effective, readily accessible as an outpatient 
and easy to perform, and does not require bowel preparation (lavage). 
An added advantage of nasogastric over colonic administration is 
potentially greater exposure of gut surface area to the new flora.[13] 
Reported complications have been related to the insertion of the NGT 
itself rather than the transplantation. Exceptions to eligibility for 
nasogastric administration are delayed bowel transit, ileus and small-
bowel Crohn’s disease. Colonoscopic insertion delivers faecal matter 
directly into the large bowel after standard lavage and is the preferred 
route for severe CDAD complicated by ileus.[13,14]
Preparation of the faeces for both methods is to liquidise the stool 
and blend it with saline or water, making a faecal suspension which is 
then filtered to remove any fibrous particles that may cause blockage 
of the NGT or colonoscopic channel.[13,14] A smaller volume of this 
suspension is used for NGT administration (30 - 50 mL), whereas 
larger volumes are used for colonoscopic insertion (400 mL). All 
modes of administration require that concurrent antimicrobial 
treatment be discontinued 24 - 48 hours before the procedure. When 
the nasogastric route is used, a PPI should be administered for 24 - 
48 hours prior to transplantation to render the stomach achlorhydric 
and increase survival of the new organisms.[15]
The definitive role of FMT as a therapeutic intervention is 
evolving, such as whether it should be considered at the time of initial 
diagnosis of CDAD or only after recurrence occurs. The preferred 
route of administration of FMT is also under investigation and may 
depend on the severity of the associated symptoms, as well as patient 
preference.
Objectives
WDGMC, an academic specialist referral hospital, is one of few 
centres in SA that offers FMT for recurrent CDAD. In this article, we 
report on the clinical profile and outcomes of a case series of FMT 
recipients. We hope to create awareness in the healthcare profession 
of who may be at risk and the importance of judicious antibiotic 
prescription to prevent this condition. We highlight clinical methods 
utilised at our hospital that appear to make FMT safe, successful and 
cost-effective. Finally, we discuss funding issues in the private health 
environment and relate these to the recently published South African 
Gastroenterology Society (SAGES) guideline.[16]
Methods
Permission for this study was obtained from the Human Research 
Ethics Committee (Medical), University of the Witwatersrand (ref. no. 
M150319). A retrospective record review of patients with recurrent 
CDAD referred for FMT between 1 January 2012 and 31 December 
2016 was conducted. Patients were referred by local clinicians to 
a medical gastroenterology practice at WDGMC. The following 
data were collected: age at time of referral, gender, associated risk 
factors, prior antibiotic treatment received for CDAD, relationship of 
recipient to donor, method of administration of FMT, and results of 
4-week follow-up for remission. Laboratory reports confirming CDI 
were obtained, where possible. The definitions used and treatment 
regimens prescribed are according to published guidelines.[17,18]
Clinical remission was assessed 4 weeks after FMT and defined 
as complete resolution of clinical symptoms (mostly diarrhoea). 
Patients were also requested to submit a stool specimen for laboratory 
confirmation of clearance of C. difficile.
Private laboratory testing for C. difficile was mainly performed 
through molecular tests (polymerase chain reaction (PCR)) that 
detect the toxin genes (tcdA/tcdB) responsible for producing toxins 
A and B. Testing for the actual toxin was sometimes also performed.
Each patient was asked if they could source a potential donor from 
family members (related), spouses/partners or friends (unrelated 
but known). If a patient was unable to source a donor, the attending 
clinician sourced an anonymous donation (unrelated and unknown) 
from previous donors. The donor was approached if they were 
still within 6 months of their last screening. If agreeable, they were 
questioned to ensure that they had remained well during this period, 
and that they had not received antibiotics or had any new piercings, 
tattoos or sexual partners.
For the evaluation of each potential donor, a confidential screening 
interview was conducted to identify any risk factors that may preclude 
donation as per the SAGES guideline.[16] If eligible, the donor then 
gave a full medical history and underwent examination. Donors 
were excluded if they had any of the following: history of antibiotic 
use in the past 3 months; history of irritable bowel syndrome 
or irregular bowel habits; history of any major gastrointestinal 
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Fig. 1. Clostridium difficile infection rates at Wits Donald Gordon Medical 
Centre, 2013 - 2016. (CDI = C. difficile infection; HAI = hospital-acquired 
infection.)
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disease (such as inflammatory bowel disease 
or malignancy); diabetes mellitus; morbid 
obesity; use of any immunosuppressive or 
chemotherapeutic agents; recent piercings 
or tattoos; or a history of high-risk sexual 
behaviour. All donors were then screened 
for HIV, hepatitis A, B and C and syphilis. 
Donor stool was tested to exclude infection 
with ova, cysts, parasites and C. difficile. 
Additional screening tests were performed 
at the discretion of the attending physician. 
Donors were prescribed a single dose of 
an osmotic laxative containing macrogol 
(polyethylene glycol) to be taken with water 
the night before the planned stool donation.
On the day of the procedure, the fresh 
stool specimen was liquidised with 200 - 400 
mL normal saline (depending on the volume 
of the sample) and passed through a gauze 
filter to remove particulate matter. For the 
nasogastric method, a PPI was administered 
to each recipient 48 hours prior to the 
procedure. After insertion of the NGT, 
placement was checked via auscultation and 
aspiration. A 60 mL volume of the sample 
was administered slowly and flushed with 
a further 60 mL normal saline. The NGT 
remained in situ for a further 20  minutes 
and was then removed. Each patient was 
observed for a further 30 minutes before 
discharge. The total time taken for the 
procedure was 60 - 120 minutes. To mini-
mise the risk of aspiration, no sedation or 
local anaesthetic throat spray was used and 
the procedure was performed with the patient 
in a seated position. For the colonoscopic 
method, standard bowel preparation was 
performed prior to the FMT procedure. 
During the FMT procedure, 300 mL of the 
total 400 mL faecal sample was placed in the 
terminal ileum, provided the terminal ileum 
was intubated, with the remaining 100 mL 
dispersed on withdrawal of the colonoscope. 
If terminal ileal intubation was not achieved, 
300 mL of the faecal sample was instilled 
into the caecum and the remaining 100 mL 
sprayed on withdrawal.
Study data were collected and managed 
using Research Electronic Data Capture 
(REDCap) which is a secure, web-based 
application designed to support data 
capture for research studies hosted at the 
Faculty of Health Sciences, University of the 
Witwatersrand.[19] Sample size estimation 
was based on the key research question to 
be answered, in this case the estimation of 
proportions (e.g. the proportion of females 
in the study group). Based on worst-case (for 
sample size) estimates of 50%, 5% precision 
and the 95% confidence level, an ideal 
sample size of 385 would be required.[20] 
The actual sample size of 27 corresponds to 
a precision of 19% (rather than 5%), which 
is a limitation of the study. Descriptive data 
analysis was carried out using SAS version 
9.4 for Windows.
Results
All 27 patients in this study group fulfilled 
the criteria for recurrent CDAD and, at 
the time of presentation, 72% had had 
between one and three previous infections. 
Three procedures (11%) were performed 
as inpatients, two from the intensive care 
unit (ICU) and one from the general 
ward. The remainder (24/27) were done 
in the outpatient gastroenterology unit. 
Laboratory-confirmed reports of CDI were 
available in 21/27 cases. Most of these 
(86%) were diagnosed by PCR, 29% with 
demonstration of C. difficile toxin and three 
patients by both methods. All patients with 
known previous treatments (26/27) had 
been treated with vancomycin, while 65% 
had also been treated with metronidazole. 
One patient had received a previous faecal 
transplant. In 24/27 of the patients, data 
were available for the median time between 
diagnosis of the first episode of laboratory-
confirmed CDAD and FMT, which was 
4  months (interquartile range (IQR) 3 - 7, 
range 0.2 - 25).
The majority of the patients in this study 
group were female (20/27, 74%), the median 
age at first visit was 57 years (IQR 37 - 72, 
range 19 - 88), and 9/27 (33%) were aged 
>65 years. In this sample, the main risk 
factors for the development of CDAD, in 
decreasing frequency, were prior antibiotic 
use (15/25, 60%), chronic use of PPIs (11/25, 
44%) and comorbid inflammatory bowel 
disease, which included ulcerative colitis and 
Crohn’s disease (11/25, 44%) (Fig. 2). Forty 
percent of the patients had three or more 
risk factors. In those with prior antibiotic 
use, antibiotics had been prescribed for the 
following conditions: gastrointestinal (5/15, 
33.3%), respiratory (4/15, 27%), and skin/
soft tissue (each 3/15, 20%).
Of the faecal donor pool, approximately 
two-thirds were either related (9/27, 33%) or 
known to the recipients as a spouse/partner 
or friend (10/27, 37%). The remainder were 
unknown to the recipients and were sourced 
from previous donors (7/27, 26%). The 
donor-recipient relationship could not be 
determined in one case. The most common 
route of administration was via NGT (21/27, 
78%), with 4/27 (15%) procedures done by 
colonoscopy and 2/27 (7%) nasoduodenal. 
Both the nasoduodenal insertions were 
for ICU patients and were administered in 
the radiology unit under X-ray guidance, 
not via endoscopy. There were no serious 
procedure-related complications, notably 
aspiration. One patient vomited 3 hours after 
administration, but the transplant was still 
effective. Another reported feeling nauseous, 
but this settled on symptomatic treatment. 
The majority of FMT recipients (23/27, 85%) 
returned for a follow-up visit after 4 weeks. 
The others were contacted telephonically. All 
the recipients experienced clinical resolution 
of their diarrhoea by 4 weeks, and there 
were no recurrences or deaths. Of those who 
submitted a stool sample for C. difficile PCR 
at 4 weeks (23/27), 20 tested negative (87%) 
and 1 tested positive (4%); 2 results could 
not be found.
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Fig. 2. Risk factors for the development of recurrent Clostridium difficile-associated diarrhoea in 
patients referred to Wits Donald Gordon Medical Centre for faecal microbiota transplant. (CDAD = 
C. difficile-associated diarrhoea; PPI = proton-pump inhibitor; IBD = inflammatory bowel disease; 
immunocompromised = individuals with comorbidity that required immunosuppressive therapy other 
than corticosteroids; other = 1 patient with diabetic gastroparesis, 2 with surgical procedures relating to 
colon cancer and 1 with surgical site sepsis after caesarean section.)
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Discussion
To date, this is the largest case series published from SA that has 
described the role of FMT in the management of recurrent CDAD. 
The success of the procedure in our context is significant, given 
the persistent burden of disease observed at WDGMC (Fig. 1). It is 
important to note that the increase in the number of infections in 2016 
may be attributable to the status of the hospital as a referral facility, 
previous diagnostic barriers in diagnosis of CDAD and mechanisms 
for laboratory reporting (which may have led to underreporting), or 
a combination thereof.[21] While there are no national surveillance 
data to confirm the trend at our hospital, it reflects similar findings 
internationally and adds urgency to the implementation of the 
South African Antimicrobial Resistance Strategy Framework.[22] This 
comprises a regulatory framework within which surveillance and 
antimicrobial stewardship in combination with infection prevention 
and control are prioritised to reduce morbidity and mortality 
associated with antibiotic-resistant infections.
While a regulatory framework is essential, clinicians need to be 
far more aware of the impact of CDAD on the individual and the 
healthcare system in which they seek care. The findings in this study 
are sobering. At the time of referral, the majority of our patients 
had suffered from between one and three infections requiring at 
least two courses of antibiotics over a median period of 4 months. 
Of the identified risk factors, prior antibiotic exposure and chronic 
PPI and corticosteroid use predominated. All these are potentially 
modifiable and even preventable with judicious prescription practice. 
With regard to the non-modifiable risk factors, namely female 
gender, older age (one-third of the patients were aged >65 years) and 
underlying inflammatory bowel disease, our findings are consistent 
with the published literature, but we had far fewer patients from long-
term care facilities.
At WDGMC the preferred mode of administration for FMT is 
via the nasogastric route in the outpatient unit. This means that 
no gastroscopy or bowel preparation is required (as in the case of 
colonoscopy) and the need for hospital admission is eliminated. The 
results from this series confirm unequivocally that this is safe and 
effective. Nasoduodenal or colonoscopic routes are only considered 
if nasogastric administration is not feasible. This method has evolved 
over the past 5 years from clinical experience based on good patient 
tolerance, the success rate and ease of administration. However, it 
counters the recently published SAGES guideline[16] that recommends 
duodenal or colonoscopic administration and inpatient observation 
overnight.
The administration of FMT via the nasogastric route at WDGMC 
also evolved from difficulties regarding funding in the private 
healthcare sector. There is currently no procedural code for FMT, 
as it is not a registered form of treatment. This forces clinicians to 
code for alternative ‘proxy’ procedures which, besides being ethically 
problematic, results in wide variations in cost to the funder and the 
patient. There is also no funding mechanism for evaluation of the 
donor, which results in most recipients carrying the costs themselves.
Study limitations
The limitations of the study are its retrospective design, small sample 
size and restriction to the private sector.
Conclusion
This case series confirms that FMT is a safe and effective therapy 
for recurrent CDAD. In most cases it can be administered via the 
nasogastric route as an outpatient. We propose that the recently 
published SAGES guideline be reviewed regarding recommendations 
for the route of administration of FMT and hospital admission. 
We hope that by making our experience available, we can assist 
healthcare funders to formalise billing procedures for FMT that 
include the costs of the donor evaluation.
More broadly, this study highlights an urgent need for the 
medical community to address antimicrobial prescription at all 
levels – governmental health policy and regulation, implementation 
in healthcare institutions, and bedside practice. It is incumbent upon 
each clinician to critically review prescription practice and implement 
appropriate changes that minimise the risk of patients developing 
these debilitating and potentially life-threatening conditions.
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